Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Guggenheim
Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $12.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 304.04% from the stock’s previous close. Several […]
Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $12.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 304.04% from the stock’s previous close. Several […]
